Evidence map›Paper›PMID 31628218›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020

Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer.

Steven J de Jongh, Jolien J J Tjalma, Marjory Koller, Matthijs D Linssen, Jasper Vonk, Michael Dobosz, Annelies Jorritsma-Smit, Jan H Kleibeuker, Geke A P Hospers, Klaas Havenga and 5 more

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Targeted Fluorescence Imaging of Bevacizumab-800CW in Patients with Neovascular Age-Related Macular Degeneration.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Steven J de JonghDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jolien J J TjalmaDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Marjory KollerDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Matthijs D LinssenDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jasper VonkDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Michael DoboszDiscovery Oncology, Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Annelies Jorritsma-SmitDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jan H KleibeukerDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Geke A P HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Klaas HavengaDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Patrick H J HemmerDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Arend KarrenbeldDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; and.
Gooitzen M van DamDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Boudewijn van EttenDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Wouter B NagengastDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands w.b.nagengast@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Negative circumferential resection margins (CRM) are the cornerstone for the curative treatment of locally advanced rectal cancer (LARC). However, in up to 18.6% of patients, tumor-positive resection margins are detected on histopathology. In this proof-of-concept study, we investigated the feasibility of optical molecular imaging as a tool for evaluating the CRM directly after surgical resection to improve tumor-negative CRM rates.

Indexed as

BevacizumabMargins of ExcisionOptical ImagingSurgery, Computer-AssistedAdultAgedDisease-Free SurvivalFemaleHumansMaleMiddle AgedRectal NeoplasmsTreatment OutcomeBevacizumabback-table fluorescence-guided imagingnear-infrared fluorescenceoptical molecular imagingvascular endothelial growth factor A

Identifiers

PMID31628218
PMCPMC7198377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.